PositiveSingles.com - the best, most trusted and largest anonymous STD dating site! Herpes Survival Kit - a specially designed pack containing everything you need to combat herpes and cold sore outbreaks (at a minimum cost to your wallet).

only search herpeshomepage.com

"The Good News about the Bad News - 
Herpes: Everything You Need to Know
"  
Terri Warren's new book - which we do endorse.

First time visitor? Please Learn about Registering and read our policy page.
{Home}{Awareness}{Research}{Treatment}{HHP FAQ}{Bookstore}{Bio/Info Page}

The Original Herpes Home Page Discussion Forums

Subject: "Ademus hsv2 therapeutic vaccine - phase 1"     Previous Topic | Next Topic
Printer-friendly copy     Email this topic to a friend    
Conferences Herpes News Topic #1596
Reading Topic #1596
muffinadmin
Member since Sep-10-04
6329 posts
Feb-03-14, 06:32 PM (CST)
Click to EMail muffin Click to send private message to muffin Click to view user profileClick to add this user to your buddy list  
"Ademus hsv2 therapeutic vaccine - phase 1"
 
http://www.news-medical.net/news/20140203/Admedus-HSV-2-therapeutic-vaccine-achieves-primary-endpoint-in-Phase-1-trial.aspx

Admedus' HSV-2 therapeutic vaccine achieves primary endpoint in Phase 1 trial
Published on February 3, 2014 at 7:39 AM · No Comments



Admedus (ASX: AHZ) today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.

The dosing of study subjects was completed in December 2013 and further analysis of the data in still ongoing. Admedus anticipates providing further study data later in the year.

“This is an encouraging result for the core vaccine technology and provides us with the basis for not only progressing the Herpes therapeutic vaccine program, but also preparing the Human Papillomavirus vaccine for initial clinical studies as a therapeutic against HPV and Cervical Cancer” said Admedus CEO Mr Lee Rodne.

The core technology is based on Professor Ian Frazer and his team’s work over the last 10 years. The technology looks at stimulating the immune response to enable a patient to fight against diseases.

“The results are very encouraging and we believe we should progress these programs forward” said Professor Ian Frazer.

“Once we complete our analysis the team will be looking to take this program into a second clinical study in patients infected with the Herpes virus”.

Currently there is no cure for Herpes and incidence is high. The US CDC estimates that 1 in 6 people in the USA between the age of 14 and 49 have contracted the infection. There is currently no cure for Herpes Simplex 2 infection.

Source: http://www.admedus.com/


  Alert | IP Printer-friendly page | Edit | Reply | Reply With Quote | Top

Conferences | Topics | Previous Topic | Next Topic

 

Advertisements appearing on this page do not constitute any endorsement of 
those products or services by HHP or its management.

All opinions expressed here by the HHP, its management and participants constitute just that, opinions.
No medical relationship with any participant is implied in any way.
Each individual's personal doctor is responsible for the medical advice and care of that person.